Compelling
Investing.com — Weight-loss medications like the popular versions made by Denmark’s Novo Nordisk A/S (CSE:) and US peer Eli Lilly (NYSE:) are the “most compelling story within the healthcare sector,” analysts at Wells Fargo said. The GLP-1 class of drugs includes blockbuster brands like Novo’s Ozempic and Wegovy and Eli Lilly’s…
Investing.com — Weight-loss medications like the popular versions made by Denmark’s Novo Nordisk A/S (CSE:) and US peer Eli Lilly (NYSE:) are the “most compelling story within the healthcare sector,” analysts at Wells Fargo said. The GLP-1 class of drugs includes blockbuster brands like Novo’s Ozempic and Wegovy and Eli Lilly’s…
Investing.com — Bank of America (BofA) adjusted its price objective for Novo Nordisk (NYSE:) shares to DKK1075 from the previous DKK1150, aligning with changes in earnings per share (EPS) forecasts. The bank’s price target for Novo’s US-listed shares was also reduced from $166 to $159.5. The adjustments come amid a…
Even-driven analysts at Raymond James came out with a bullish view on NETGEAR Inc (NASDAQ:), a beleaguered maker of networking equipment, after Windward Management, a Florida-based activist hedge fund, recently disclosed a 4.2% stake in the company, and Windward’s CEO Marc Chalfin published an open letter outlining massive value creation…
